高危阳性淋巴结宫颈癌的同步整合加量放疗
本研究回顾性分析了2015年1月至2017年6月接受根治性放化疗的69例局部晚期宫颈癌患者(23例接受同步整合加量SIB,46例淋巴结阴性对照),中位随访30.9个月。SIB组3个月原发肿瘤完全缓解率100%,淋巴结体积完全缓解率83%;3年OS、LRFS、RRFS、DRFS分别为69%、91%、79%、77%。SIB可安全给予阳性盆腔淋巴结60 Gy/25次而不增加毒性。
要点
- SIB对影像学阳性盆腔淋巴结给予60 Gy/25次,未增加毒性。
- SIB组3个月原发肿瘤完全缓解率100%,淋巴结体积完全缓解率83%。
- SIB组3年OS 69%、LRFS 91%、RRFS 79%、DRFS 77%。
核心结论
- 采用SIB对影像学异常盆腔淋巴结给予60 Gy/25次放化疗,与淋巴结阴性患者相比毒性未增加。
- 阳性淋巴结状态的不良影响可能被SIB高剂量沉积所抵消,但需更大样本前瞻性研究证实。
研究设计与样本
- 回顾性分析2015年1月至2017年6月接受根治性放化疗(每周顺铂)的局部晚期宫颈癌患者69例,其中SIB组23例、淋巴结阴性对照46例,中位随访30.9个月。
- 所有患者接受45 Gy/25次,SIB剂量60 Gy/25次,采用IMRT/VMAT,后接高剂量率近距离放疗28 Gy/4次。
- 以总生存(OS)、治疗后肿瘤反应(基于3和12个月横断面影像的LRFS、RRFS、DRFS)和毒性为结局指标。
主要发现
- SIB组3个月原发肿瘤完全缓解率为100%,接受SIB的淋巴结体积完全缓解率为83%。
- SIB组3年OS为69%、LRFS为91%、RRFS为79%、DRFS为77%。
关键数值与推荐
- SIB组放疗剂量:45 Gy/25次,同步整合加量60 Gy/25次,采用IMRT/VMAT。
- 近距离放疗剂量:高剂量率28 Gy/4次。
临床怎么用
- 对局部晚期宫颈癌影像学阳性盆腔淋巴结可采用SIB加量至60 Gy/25次,不增加毒性。
- 需注意本研究为回顾性小样本,阳性淋巴结状态的不良影响可能被高剂量抵消的结论尚待前瞻性研究确认。
局限性
- 回顾性研究,样本量较小(SIB组23例,对照组46例)。
- 随访时间中位30.9个月,尚不足以评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lymph node metastases presenting with locally advanced cervical cancer are poor prognostic features. Modern radiotherapy approaches enable dose escalation to radiologically abnormal nodes. This study reports the results of a policy of a simultaneous integrated boost (SIB) in terms of treatment outcomes. MATERIALS AND METHODS: Patients treated with radical chemoradiation with weekly cisplatin for locally advanced cervical cancer including an SIB to radiologically abnormal lymph nodes were analysed. All patients received a dose of 45 Gy in 25 fractions and a SIB dose of 60 Gy in 25 fractions using intensity modulated radiotherapy/volumetric modulated arc therapy, followed by high dose rate brachytherapy of 28 Gy in 4 fractions. A control cohort with radiologically negative lymph nodes was used to compare impact of the SIB in node positive patients. Treatment outcomes were measured by overall survival (OS), post treatment tumour response and toxicities. The tumour response was based on cross sectional imaging at 3 and 12 months and recorded as local recurrence free survival (LRFS), regional recurrence free survival (RRFS) and distant recurrence free survival (DRFS). RESULTS: In between January 2015 and June 2017, a total of 69 patients with a median follow up of 30.9 months (23 SIB patients and 46 control patients) were identified. The complete response rate at 3 months was 100% in the primary tumour and 83% in the nodal volume receiving SIB. The OS, LRFS, RRFS and DRFS at 3 years of the SIB cohort were 69%, 91%, 79% and 77% respectively. High doses can be delivered to regional pelvic lymph nodes using SIB without excessive toxicity. CONCLUSION: Using a SIB, a total dose of 60 Gy in 25 fractions chemoradiation can be delivered to radiologically abnormal pelvic nodes with no increase in toxicity compared to node negative patients. The adverse impact of positive nodal status may be negated by high dose deposition using SIB, but larger prospective studies are required to confirm this observation.
引用
- Jayatilakebanda I, Tsang YM, Hoskin P, et al. High dose simultaneous integrated boost for node positive cervical cancer. Radiat Oncol. 2021. PMID: 34001158. doi:10.1186/s13014-021-01818-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。